A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway

Journal of Immunology

Volumn 160, Issue 7, 1998, Pages 3419-3426

  Challita Eid, Pia M ^a   Penichet, Manuel L ^b   Shin, Seung Uon ^b,c   Poles, Tina ^a   Mosammaparast, Nima ^a   Mahmood, Kutubuddin ^a   Slamon, Dennis J ^b   Morrison, Sherie L ^b   Rosenblatt, Joseph D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; HYBRID PROTEIN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; GENE TRANSFER; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, CD80; BASE SEQUENCE; BINDING SITES, ANTIBODY; CELL MEMBRANE; CHO CELLS; CRICETINAE; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0032055860     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261.
2. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
3. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
4. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421.
5. Dohring, C., L. Angman, G. Spagnoli, and A. Lanzavecchia. 1994. T-helper- and accessory cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 57:754.
6. + T lymphocytes in vitro. Cell. Immunol. 179:146.
7. Hodge, J. W., J. P. McLaughlin, S. I. Abrams, W. L. Shupert, J. Schlom, and J. A. Kantor. 1995. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55:3598.
8. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor. 1994. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54:5552.
9. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721.
10. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177.
11. Slamon, D. J. 1987. Proto-oncogenes and human cancers. N. Engl. J. Med. 317: 955.
12. Bacus, S. S., J. W. Bacus, D. J. Slamon, and M. F. Press. 1990. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch. Pathol. Lab. Med. 114:164.
13. Natali, P. G., M. R. Nicotra, A. Bigotti, I. Venturo, D. J. Slamon, B. M. Fendly, and A. Ullrich. 1990. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 45:457.
14. Pegram, M., A. Lipton, R. Pietras, D. Hayes, B. Weber, J. Baselga, D. Tripathy, T. Twadell, J. Glaspy, and D. Slamon. 1995. Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 14:106.
15. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, and L. Norton. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737.
16. Miller, D. A., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980.
17. Carter, P., R. F. Kelley, M. L. Rodrigues, B. Snedecor, M. Covarrubias, M. D. Velligan, W. L. Wong, A. M. Rowland, C. E. Kotts, M. E. Carver, M. Yang, J. H. Bourell, M. Shepard, and D. Henner. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 10:163.
18. Coloma, M. J., A. Hastings, L. A. Wims, and S. L. Morrison. 1992. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods 152:89.
19. Shin, S. U., and S. L. Morrison. 1990. Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting. Proc. Natl. Acad. Sci. USA 87:5322.
20. Coloma, M. J., and S. L. Morrison. 1997. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15:159.
21. Guo, Y., Y. Wu, M. Zhao, X. P. Kong, and Y. Liu. 1995. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J. Exp. Med. 181:1345.
22. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561.
23. Morrison, S. L. 1992. In vitro antibodies: strategies for production and application. Annu. Rev. Immunol. 10:239.
24. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
25. Gaiewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
26. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
27. Chamberlain, R. S., M. W. Carroll, V. Bronte, P. Hwu, S. Warren, J. C. Yang, M. Nishimura, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1996. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56:2832.
28. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
29. Greenfield, E. A., E. Howard, T. Paradis, K. Nguyen, F. Benazzo, P. McLean, P. Hollsberg, G. Davis, D. A. Hafler, A. H. Sharpe, G. J. Freeman, and V. K. Kuchroo. 1997. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J. Immunol. 158:2025.
30. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
31. McGrath, J. P., X. Cao, A. Schutz, P. Lynch, T. Ebendal, M. J. Coloma, S. L. Morrison, and S. D. Putney. 1997. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J. Neurosci. Res. 47:123.
32. Tagliabue, E., F. Centis, M. Campiglio, A. Mastroianni, S. Martignone, R. Pellegrini, P. Casalini, C. Lanzi, S. Menard, and M. I. Colnaghi. 1991. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer 47:933.
33. Harris, L., and S. M. Swain. 1996. The role of primary chemotherapy in early breast cancer. Semin. Oncol. 23:31.
34. Sledge, G. W., Jr. 1996. Adjuvant therapy for early stage breast cancer. Semin. Oncol. 23:51.
35. Seidman, A. D. 1996. Chemotherapy for advanced breast cancer: a current perspective. Semin. Oncol. 23:55.
36. Bearman, S. I., E. J. Shpall, R. B. Jones, P. J. Cagnoni, and M. Ross. 1996. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin. Oncol. 23:60.
37. Rodrigues, M. L., L. G. Presta, C. E. Kotts, C. Wirth, J. Mordenti, G. Osaka, W. L. Wong, A. Nuijens, B. Blackburn, and P. Carter. 1995. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55:63.
38. Becker, J. C., N. Varki, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98:2801.
39. Becker, J. C., J. D. Pancook, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183:2361.
40. Becker, J. C., N. Varki, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA 93:7826.
41. Sabzevari, H., S. D. Gillies, B. M. Mueller, J. D. Pancook, and R. A. Reisfeld 1994. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA 91:9626.
42. Harvill, E. T., J. M. Fleming, and S. L. Morrison. 1996. In vivo properties of an IgG3-IL-2 fusion protein: a general strategy for immune potentiation. J. Immunol. 157:3165.
43. Harvill, E. T., and S. L. Morrison. 1996. An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R α subunit: real time measurement of ligand binding. Mol. Immunol. 33:1007.
44. Gerstmayer, B., U. Altenschmidt, M. Hoffmann, and W. Wels. 1997. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J. Immunol. 158: 4584.
45. Guo, Y. J., X. Y. Che, F. Shen, T. P. Xie, J. Ma, X. N. Wang, S. G. Wu, D. D. Anthony, and M. C. Wu. 1997. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat. Med. 3:451.